
|Videos|January 30, 2017
Dr. Weiss on PD-L1 Biomarker in Lung Cancer
Author(s)Jared Weiss, MD
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.
Advertisement
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.
PD-L1 is a much contested biomarker in this field, Weiss explains. While its positive predictive value is beneficial, PD-L1 expression does not provide a stable negative predictor.
According to Weiss, researchers should move on from PD-L1 and start looking into different biomarkers such as mismatch repair, mutational load and mRNA expression signatures, which all show promise.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































